• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Curis Enters into Agreement for Emavusertib Combination Study in Melanoma

    PR NEWSWIRE

    FDA Lifts Partial Clinical Hold on TakeAim Leukemia Trial Emavusertib in AML/MDS

    ONCLIVE

    FDA lifts partial hold on Curis` PhI/II leukemia study as biotech raises $15M 

    ENDPTS

    FDA puts Curis` leukemia trial on partial hold after patient death

    FIERCE BIOTECH

    FDA lets biotech resume enrollment for part of phase 1/2 leukemia study

    FIERCEBIOTECH

    FDA lifts partial clinical hold on Curis lymphoma study

    LABIOTECH

    Curis Announces Encouraging Emavusertib Data at the 2022 ASCO

    PRNEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.